Payment overview · 2025
General Payments
$1,497.85
76 reported records · 17 companies
Healthcare provider profile · identity verified
Stephen Mark Winfield, MD
Allopathic & Osteopathic Physicians|Family Medicine · CHAMPLAIN, NY · NPI 1992156970
Verified facts
What the public records show
CMS Open Payments records show Stephen Mark Winfield, MD received $1,497.85 in general payments during 2025 across 76 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Trelegy Ellipta, Wegovy.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $287.14 | 19.2% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $247.75 | 16.5% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $191.95 | 12.8% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $150.18 | 10.0% | 12 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $128.16 | 8.6% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $76.45 | 5.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.67 | 4.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.75 | 4.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.90 | 3.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.50 | 3.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.81 | 2.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $35.79 | 2.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.67 | 1.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.50 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.48 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.89 | 1.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.26 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,497.85 | 76 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $173.66 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $160.79 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $153.30 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $129.83 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $108.53 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $100.88 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $100.88 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $85.19 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $76.45 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $72.61 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $68.75 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $68.67 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $68.67 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $66.75 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $65.38 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $55.24 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.14 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $43.81 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $35.79 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $35.22 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.92 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.98 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 92 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 104 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
104 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 436 | 169 |
| Metformin Hcl | Metformin Hcl | 193 | 76 |
| Omeprazole | Omeprazole | 182 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 172 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 153 | 56 |
| Lisinopril | Lisinopril | 153 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 56 |
| Losartan Potassium | Losartan Potassium | 149 | 54 |
| Prednisone | Prednisone | 141 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 46 |
| Furosemide | Furosemide | 120 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 104 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 41 |
| Famotidine | Famotidine | 96 | 40 |
| Potassium Chloride | Potassium Chloride | 96 | 40 |
| Eliquis | Apixaban | 92 | 32 |
| Ozempic | Semaglutide | 89 | 25 |
| Allopurinol | Allopurinol | 83 | 32 |
| Ezetimibe | Ezetimibe | 80 | 26 |
| Clonazepam | Clonazepam | 78 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 18 |
| Gabapentin | Gabapentin | 73 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 28 |
| Simvastatin | Simvastatin | 68 | 27 |
| Trazodone Hcl | Trazodone Hcl | 65 | 26 |
| Tramadol Hcl | Tramadol Hcl | 62 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 22 |
| Mupirocin | Mupirocin | 53 | 36 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 48 |
| Sertraline Hcl | Sertraline Hcl | 52 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 50 | 44 |
| Jardiance | Empagliflozin | 48 | 19 |
| Montelukast Sodium | Montelukast Sodium | 45 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 16 |
| Nystatin | Nystatin | 43 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 30 |
| Azithromycin | Azithromycin | 41 | 35 |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | 11 |
| Cephalexin | Cephalexin | 32 | 30 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Lorazepam | Lorazepam | 30 | 21 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | 15 |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | 16 |
| Finasteride | Finasteride | 29 | 11 |
| Fluconazole | Fluconazole | 28 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 16 |
| Latanoprost | Latanoprost | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 26 | suppressed |
| Colchicine | Colchicine | 26 | 11 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 21 |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 24 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 15 |
| Ramipril | Ramipril | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | 12 |
| Alendronate Sodium | Alendronate Sodium | 20 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Wegovy | Semaglutide | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Jublia | Efinaconazole | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,497.85 · 76 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAPVAXIVE, CREON, ELIQUIS, EVENITY, FARXIGA, GARDASIL 9, INSPIRE, KRYSTEXXA, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error